

PTC THERAPEUTICS, INC.  
Form 4  
June 28, 2013

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Koppel Adam

(Last) (First) (Middle)

C/O BROOKISDE CAPITAL  
MANAGEMENT, LLC, JOHN  
HANCOCK TOWER, 200  
CLARENDON ST.

(Street)

BOSTON, MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
PTC THERAPEUTICS, INC.  
[PTCT]

3. Date of Earliest Transaction  
(Month/Day/Year)  
06/25/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common Stock	06/25/2013		C	1,083,333 A	1,083,333	I	See Footnote (2)
Common Stock	06/25/2013		P	1,250,000 A \$ 15	2,333,333	I	See Footnote (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Security (Instr. 3 and 4)
					(A)	(D)	Date Exercisable	Expiration Date	
Series Four Senior Preferred Stock	(1)	03/07/2013		A	1,083,333		(1)	(1)	Common Stock
Series Four Senior Preferred Stock	(1)	06/25/2013		C	1,083,333		(1)	(1)	Common Stock

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Koppel Adam C/O BROOKISDE CAPITAL MANAGEMENT, LLC JOHN HANCOCK TOWER, 200 CLARENDON ST. BOSTON, MA 02116	X			

## Signatures

/s/ Dr. Adam Koppel  
06/27/2013

\*\*Signature of Reporting Person  
Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) All outstanding shares of Series Four Senior Preferred Stock were automatically converted into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration.

## Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

(2) Dr. Adam Koppel is a Managing Director of Brookside Capital Management, LLC ("BCM"). BCM is the sole general partner of Brookside Capital Investors, L.P. ("BCI"), which is the general partner of Brookside Capital Partners Fund, L.P. ("BCP Fund"). By virtue of these relationships, Dr. Koppel may be deemed to beneficially own the securities held by the BCP Fund. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

(3) BCM is also the sole general partner of Brookside Capital Investors II, L.P. ("BCI II"). BCI II is the sole general partner of Brookside Capital Trading Fund, L.P. ("BCT Fund"). By virtue of these relationships, Dr. Koppel may be deemed to beneficially own the securities held by the BCT Fund. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.